\n<\/p>\n
April 21, 2026<\/p>\n
1 min watch<\/p>\n<\/div>\n
\n\n\nAdd topic to email alerts\n<\/span>\n<\/p>\n\n\n\nReceive an email when new articles are posted on \n<\/p>\n\nPlease provide your email address to receive an email when new articles are posted on .<\/p>\n<\/div>\n<\/div>\n” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nIn this Healio video exclusive, Leonard H. Calabrese, DO, <\/b>chief medical editor of Healio Rheumatology<\/i>, highlights the latest cover story on the current state, and future, of therapeutic drug monitoring within the specialty.<\/p>\n\u201cIn rheumatology, we behind many other professions [in therapeutic drug monitoring],\u201d he said. \u201cWe are making some progress in hydroxychloroquine, but there are many other drugs to cover.\u201d <\/p>\nCalabrese additionally noted a feature story on the potential implications of capping education loans for medical students and those entering advanced practice nursing programs. <\/p>\nA proposed rule from the U.S. Department of Education would impose a yearly borrowing limit of $20,500 and a lifetime limit of $100,000 for graduate students, unless they are enrolled in programs that meet a new definition of a professional degree.<\/p>\nIncluded in that new definition are 11 core programs \u2014 medicine, osteopathic medicine, dentistry, pharmacy, optometry, veterinary medicine, podiatry, chiropractic, law, theology and clinical psychology. <\/p>\nLimits for these programs would be set at $50,000 annually and $200,000 in total. Advanced practice nursing programs are excluded from this new definition.<\/p>\n\u201cI think this is terrible,\u201d Calabrese said. <\/p>\nCalabrese meanwhile applauded the FDA for introducing a new approval process for targeted individualized therapies, including genome editing and RNA-based therapies, intended to treat rare and ultra rare diseases in which randomized controlled trials are not feasible.<\/p>\n\u201cThis is particular for genetic therapies, but I think will help us [in rheumatology] down the line,\u201d he said.<\/p>\nLastly, Calabrese discussed a Q&A with one of the researchers behind a recent study that found the chemical structure of the Borrelia burgdorferi<\/i> cell wall may dictate the frequency and severity of Lyme arthritis. These results could have implications for future treatment.<\/p>\n\u201cI found this to be a very interesting article on some work from Northwestern University Feinberg School of Medicine, regarding some structural aspects of Borrelia<\/i> <\/i>that may lead to the actual generation of inflammatory arthritis,\u201d he said.<\/p>\nFor more information:<\/h2>\n Leonard H. Calabrese, DO,<\/b> can be reached at calabrl@ccf.org or at rheumatology@healio.com. <\/p>\n
\nReceive an email when new articles are posted on \n<\/p>\n\nPlease provide your email address to receive an email when new articles are posted on .<\/p>\n<\/div>\n<\/div>\n” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nIn this Healio video exclusive, Leonard H. Calabrese, DO, <\/b>chief medical editor of Healio Rheumatology<\/i>, highlights the latest cover story on the current state, and future, of therapeutic drug monitoring within the specialty.<\/p>\n\u201cIn rheumatology, we behind many other professions [in therapeutic drug monitoring],\u201d he said. \u201cWe are making some progress in hydroxychloroquine, but there are many other drugs to cover.\u201d <\/p>\nCalabrese additionally noted a feature story on the potential implications of capping education loans for medical students and those entering advanced practice nursing programs. <\/p>\nA proposed rule from the U.S. Department of Education would impose a yearly borrowing limit of $20,500 and a lifetime limit of $100,000 for graduate students, unless they are enrolled in programs that meet a new definition of a professional degree.<\/p>\nIncluded in that new definition are 11 core programs \u2014 medicine, osteopathic medicine, dentistry, pharmacy, optometry, veterinary medicine, podiatry, chiropractic, law, theology and clinical psychology. <\/p>\nLimits for these programs would be set at $50,000 annually and $200,000 in total. Advanced practice nursing programs are excluded from this new definition.<\/p>\n\u201cI think this is terrible,\u201d Calabrese said. <\/p>\nCalabrese meanwhile applauded the FDA for introducing a new approval process for targeted individualized therapies, including genome editing and RNA-based therapies, intended to treat rare and ultra rare diseases in which randomized controlled trials are not feasible.<\/p>\n\u201cThis is particular for genetic therapies, but I think will help us [in rheumatology] down the line,\u201d he said.<\/p>\nLastly, Calabrese discussed a Q&A with one of the researchers behind a recent study that found the chemical structure of the Borrelia burgdorferi<\/i> cell wall may dictate the frequency and severity of Lyme arthritis. These results could have implications for future treatment.<\/p>\n\u201cI found this to be a very interesting article on some work from Northwestern University Feinberg School of Medicine, regarding some structural aspects of Borrelia<\/i> <\/i>that may lead to the actual generation of inflammatory arthritis,\u201d he said.<\/p>\nFor more information:<\/h2>\n Leonard H. Calabrese, DO,<\/b> can be reached at calabrl@ccf.org or at rheumatology@healio.com. <\/p>\n
” data-action=subscribe>\nSubscribe\n<\/button>\n<\/div>\n<\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nIn this Healio video exclusive, Leonard H. Calabrese, DO, <\/b>chief medical editor of Healio Rheumatology<\/i>, highlights the latest cover story on the current state, and future, of therapeutic drug monitoring within the specialty.<\/p>\n\u201cIn rheumatology, we behind many other professions [in therapeutic drug monitoring],\u201d he said. \u201cWe are making some progress in hydroxychloroquine, but there are many other drugs to cover.\u201d <\/p>\nCalabrese additionally noted a feature story on the potential implications of capping education loans for medical students and those entering advanced practice nursing programs. <\/p>\nA proposed rule from the U.S. Department of Education would impose a yearly borrowing limit of $20,500 and a lifetime limit of $100,000 for graduate students, unless they are enrolled in programs that meet a new definition of a professional degree.<\/p>\nIncluded in that new definition are 11 core programs \u2014 medicine, osteopathic medicine, dentistry, pharmacy, optometry, veterinary medicine, podiatry, chiropractic, law, theology and clinical psychology. <\/p>\nLimits for these programs would be set at $50,000 annually and $200,000 in total. Advanced practice nursing programs are excluded from this new definition.<\/p>\n\u201cI think this is terrible,\u201d Calabrese said. <\/p>\nCalabrese meanwhile applauded the FDA for introducing a new approval process for targeted individualized therapies, including genome editing and RNA-based therapies, intended to treat rare and ultra rare diseases in which randomized controlled trials are not feasible.<\/p>\n\u201cThis is particular for genetic therapies, but I think will help us [in rheumatology] down the line,\u201d he said.<\/p>\nLastly, Calabrese discussed a Q&A with one of the researchers behind a recent study that found the chemical structure of the Borrelia burgdorferi<\/i> cell wall may dictate the frequency and severity of Lyme arthritis. These results could have implications for future treatment.<\/p>\n\u201cI found this to be a very interesting article on some work from Northwestern University Feinberg School of Medicine, regarding some structural aspects of Borrelia<\/i> <\/i>that may lead to the actual generation of inflammatory arthritis,\u201d he said.<\/p>\nFor more information:<\/h2>\n Leonard H. Calabrese, DO,<\/b> can be reached at calabrl@ccf.org or at rheumatology@healio.com. <\/p>\n
Back to Healio<\/button><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\nIn this Healio video exclusive, Leonard H. Calabrese, DO, <\/b>chief medical editor of Healio Rheumatology<\/i>, highlights the latest cover story on the current state, and future, of therapeutic drug monitoring within the specialty.<\/p>\n\u201cIn rheumatology, we behind many other professions [in therapeutic drug monitoring],\u201d he said. \u201cWe are making some progress in hydroxychloroquine, but there are many other drugs to cover.\u201d <\/p>\nCalabrese additionally noted a feature story on the potential implications of capping education loans for medical students and those entering advanced practice nursing programs. <\/p>\nA proposed rule from the U.S. Department of Education would impose a yearly borrowing limit of $20,500 and a lifetime limit of $100,000 for graduate students, unless they are enrolled in programs that meet a new definition of a professional degree.<\/p>\nIncluded in that new definition are 11 core programs \u2014 medicine, osteopathic medicine, dentistry, pharmacy, optometry, veterinary medicine, podiatry, chiropractic, law, theology and clinical psychology. <\/p>\nLimits for these programs would be set at $50,000 annually and $200,000 in total. Advanced practice nursing programs are excluded from this new definition.<\/p>\n\u201cI think this is terrible,\u201d Calabrese said. <\/p>\nCalabrese meanwhile applauded the FDA for introducing a new approval process for targeted individualized therapies, including genome editing and RNA-based therapies, intended to treat rare and ultra rare diseases in which randomized controlled trials are not feasible.<\/p>\n\u201cThis is particular for genetic therapies, but I think will help us [in rheumatology] down the line,\u201d he said.<\/p>\nLastly, Calabrese discussed a Q&A with one of the researchers behind a recent study that found the chemical structure of the Borrelia burgdorferi<\/i> cell wall may dictate the frequency and severity of Lyme arthritis. These results could have implications for future treatment.<\/p>\n\u201cI found this to be a very interesting article on some work from Northwestern University Feinberg School of Medicine, regarding some structural aspects of Borrelia<\/i> <\/i>that may lead to the actual generation of inflammatory arthritis,\u201d he said.<\/p>\nFor more information:<\/h2>\n Leonard H. Calabrese, DO,<\/b> can be reached at calabrl@ccf.org or at rheumatology@healio.com. <\/p>\n
In this Healio video exclusive, Leonard H. Calabrese, DO, <\/b>chief medical editor of Healio Rheumatology<\/i>, highlights the latest cover story on the current state, and future, of therapeutic drug monitoring within the specialty.<\/p>\n
\u201cIn rheumatology, we behind many other professions [in therapeutic drug monitoring],\u201d he said. \u201cWe are making some progress in hydroxychloroquine, but there are many other drugs to cover.\u201d <\/p>\n
Calabrese additionally noted a feature story on the potential implications of capping education loans for medical students and those entering advanced practice nursing programs. <\/p>\n
A proposed rule from the U.S. Department of Education would impose a yearly borrowing limit of $20,500 and a lifetime limit of $100,000 for graduate students, unless they are enrolled in programs that meet a new definition of a professional degree.<\/p>\n
Included in that new definition are 11 core programs \u2014 medicine, osteopathic medicine, dentistry, pharmacy, optometry, veterinary medicine, podiatry, chiropractic, law, theology and clinical psychology. <\/p>\n
Limits for these programs would be set at $50,000 annually and $200,000 in total. Advanced practice nursing programs are excluded from this new definition.<\/p>\n
\u201cI think this is terrible,\u201d Calabrese said. <\/p>\n
Calabrese meanwhile applauded the FDA for introducing a new approval process for targeted individualized therapies, including genome editing and RNA-based therapies, intended to treat rare and ultra rare diseases in which randomized controlled trials are not feasible.<\/p>\n
\u201cThis is particular for genetic therapies, but I think will help us [in rheumatology] down the line,\u201d he said.<\/p>\n
Lastly, Calabrese discussed a Q&A with one of the researchers behind a recent study that found the chemical structure of the Borrelia burgdorferi<\/i> cell wall may dictate the frequency and severity of Lyme arthritis. These results could have implications for future treatment.<\/p>\n
\u201cI found this to be a very interesting article on some work from Northwestern University Feinberg School of Medicine, regarding some structural aspects of Borrelia<\/i> <\/i>that may lead to the actual generation of inflammatory arthritis,\u201d he said.<\/p>\nFor more information:<\/h2>\n
Leonard H. Calabrese, DO,<\/b> can be reached at calabrl@ccf.org or at rheumatology@healio.com. <\/p>\n
![\"healio](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/rheum.svg?la=en&h=44&w=141&hash=EBAD778B57889935130139D3FF110538\")
\n<\/div>\n<\/div>\n<\/div>\n